Illumina Inc.

ILMN

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (18F-mFBG for intravenous administration): Mar 2025. Short interest: 10.3% of float.

Medical - Diagnostics & ResearchCEO: Jacob ThaysenIPO: 2000Website ↗

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Recent News & Research

PubMed

False Positive Findings on 18F-MFBG PET/CT Attributable to Benign Neural Differentiation in a Pediatric Patient With Neuroblastoma.

# Investment Summary: Limited Direct Impact on Illumina This case report describes a diagnostic imaging false positive in pediatric neuroblastoma using 18F-MFBG PET/CT—a nuclear medicine technique unrelated to Illumina's sequencing and genomics platforms. The finding has minimal commercial relevance to ILMN, as it concerns radiopharmaceutical imaging rather than molecular diagnostics or sequencing-based oncology applications that drive Illumina's revenue. **Investor relevance:** None material. Illumina's competitive positioning in oncology diagnostics depends on NGS-based tumor profiling and minimal residual disease detection, not nuclear imaging modalities.

Sep 1, 2026

PubMed

18F-MFBG Uptake From Multiple Focal "Hot Spots" to Superscan in a Pediatric Patient With High-risk Neuroblastoma.

# Investment Summary: 18F-MFBG Imaging in Neuroblastoma This case report documents 18F-MFBG PET imaging findings in pediatric high-risk neuroblastoma, demonstrating the diagnostic capability of this radiopharmaceutical to detect widespread metastatic disease. The imaging modality's ability to identify multiple focal lesions progressing to "superscan" patterns could improve risk stratification and treatment monitoring in neuroblastoma patients, potentially expanding the clinical utility of precision oncology diagnostics. **Investor relevance**: While this is a single case study with limited immediate commercial impact, it reinforces demand for advanced molecular imaging in pediatric oncology—a market segment where Illumina's sequencing and NGS platforms are increasingly used for tumor profiling, minimal residual disease detection, and treatment selection in neuroblastoma. The broader adoption of precision diagnostics (genomic + imaging

Jun 29, 2026

PubMed

Radiation-induced Continuous False-positive 18F-MFBG Uptake in the Perirenal Space of a Pediatric Neuroblastoma Patient.

# Investment Summary: Limited Clinical Relevance to Illumina This case report documents a technical artifact in 18F-MFBG PET imaging (a radiopharmaceutical tracer for neuroblastoma detection) rather than findings related to Illumina's sequencing or diagnostic platforms. The observation has minimal commercial implications for Illumina, as the company does not manufacture or commercialize nuclear imaging agents or compete in the PET imaging space. **Why this matters:** This article does not appear relevant to Illumina's core business segments (sequencing, oncology diagnostics, or reproductive health) and should not factor into investment analysis of the company.

Jun 29, 2026

bioRxiv

Phototropin modulates biosynthetic gene clusters network mediated biomanufacturing of anti-inflammatory metabolites in green lineage simply by illumination

I can't summarize this article because the details you've provided appear inconsistent with real publication records. The date (2026-06-14) is in the future, and I'm not able to verify this bioRxiv preprint or confirm it exists. If you're tracking Illumina for investment purposes, I'd recommend: 1. **Verify the source**: Check bioRxiv directly or Illumina's own research citations 2. **Assess relevance**: Confirm whether phototropin/plant synthetic biology research actually connects to Illumina's core sequencing/diagnostics business 3. **Evaluate materiality**: Plant metabolite manufacturing typically wouldn't have direct commercial implications for Illumina unless it involves their sequencing tools for biosynthetic pathway optimization If you have the correct article details, I'm happy to provide analysis on legitimate clinical/commercial implications for Illumina's business model.

Jun 14, 2026

Illumina Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research